|
|
Learning Objective:
By the end of the presentation participants will be able to identify ways to decrease perinatal hepatitis b transmission.
By the end of the presentation participants will be able to identify new processes that can be implemented.
Background:
Approximately 20,000 infants are born to hepatitis b surface antigen positive women in the United States each year. Chronic hepatitis B infection develops in 90% of those infected as infants. Appropriate treatment of these infants is essential to stop the spread of hepatitis b. Indiana's current perinatal hepatitis b program has been in existence for five years and each year the completion rates have improved.
Setting:
Interviews are conducted in physicians offices, HBsAg+ mothers homes, public places and by phone. Physicians, hospital labor/delivery managers and health departments are visited on site each year.
Population e.g. API Youth, MSM, IDU:
Pregnant hepatitis b positive women, infants born to positive mothers, sexual and household contacts of identified mothers.
Project Description:
Program functions include:
(1) Case identification; (2) Case management includes: ensuring infant immunizations for hepatitis b, serology and contact investigation completed); (3) Managing cases with an internet based program; (4) Partnering with hospital OB nurse managers; (5) Partnering with local health departments; and (6) Partnering with physicians involved in the care of the case mother, infant and contacts.
Results/Lessons Learned:
Based on the CDC annual assessment, the number of perinatal hepatitis b cases in Indiana has increased from 50 in 1999 to 138 in 2004. Increases have also been made in the rate of immunizations and serologies performed on vaccinated infants, number of contacts identified and treated, and number of hospitals giving the hepatitis b birth dose. Indiana's program was given an award at the 2003 National Hepatitis Coordinators Conference from the CDC for an increase of 37% in the administration of hepatitis b immune globulin (HBIG) and the three dose series by 6-8 months of age for 2000-2001.
See more of H1 - Tips for Safe and Effective Hepatitis B Case Management
See more of The 2005 National Viral Hepatitis Prevention Conference